Class Labeling For Anti-epileptics Embraces Lessons From Antidepressants

Anti-epileptic drug sponsors have until mid-January to decide whether to fight FDA-mandated labeling changes and a REMS program after a meta-analysis showed a statistically significant increase in suicidality.